Aug 13, 2025
Novel Mechanism Demonstrates Clinically Meaningful Prevention of Weight Rebound and Metabolic Benefits After Stopping GLP-1 Therapy
-
Primary Endpoint met: Statistically significant reduction in blood-fat levels after eating (-51.9%)
-
Multiple secondary endpoints met: Including statistically significant reduction in weight regain (-34%) compared to placebo, and improvement in cardiometabolic risk factors with RDX-002
-
Favorable safety and tolerability profile: No SAEs or discontinuation due to AEs consistent with prior studies
April 23, 2024
Response Pharmaceuticals Announces Enrollment of First Patients in a Phase 2 Study Evaluating RDX-002, a Novel Small Molecule iMTP Inhibitor, in Patients Discontinuing GLP-1 Agonists & Clinical Presentation at Obesity Week
August 17, 2023
Response Pharmaceuticals Announces Successful Completion of Phase 1B Clinical Trial for RDX-002, a Novel Small Molecule for the Treatment of Antipsychotic-Induced Weight Gain
November 21, 2022
Response Pharmaceuticals Closes $8 Million Series A Financing to Fund Clinical Trials for Patients Suffering from Antipsychotic Induced Weight Gain
August 17, 2023
Response Pharmaceuticals Announces Successful Completion of Phase 1B Clinical Trial for RDX-002, a Novel Small Molecule for the Treatment of Antipsychotic-Induced Weight Gain
November 21, 2022
Response Pharmaceuticals Closes $8 Million Series A Financing to Fund Clinical Trials for Patients Suffering from Antipsychotic Induced Weight Gain
April 23, 2024
Response Pharmaceuticals Announces Enrollment of First Patients in a Phase 2 Study Evaluating RDX-002, a Novel Small Molecule iMTP Inhibitor, in Patients Discontinuing GLP-1 Agonists & Clinical Presentation at Obesity Week